research use only

Diphenhydramine Histamine Receptor antagonist

Name: Diphenhydramine
Brand: Selleck Chemicals
SKU: E4827
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E4827

Diphenhydramine is a first-generation antihistamine and sedative that acts as an antagonist of the H1 receptor and is used for treating acute allergic reactions. It is FDA-approved as an adjunct to epinephrine and corticosteroids and exhibits anticholinergic and antiemetic effects.

Chemical Structure

Molecular Weight: 255.36

Jump to

Quality Control

Batch: E482701 DMSO]51 mg/mL]false]Ethanol]51 mg/mL]false]Water]Insoluble]false Purity: 99.07%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.07

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Histamine Receptor Inhibitors	GSK2879552 Dihydrochloride JNJ-7777120 Mianserin HCl Ebastine Astemizole Ciproxifan Maleate Rupatadine Lafutidine Cloperastine hydrochloride Mizolastine

Solubility

In vitro
Batch:

DMSO : 51 mg/mL (199.71 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	255.36	Formula	C₁₇H₂₁NO	Storage (From the date of receipt)	2 years -20°C liquid
CAS No.	58-73-1	Download SDF		Storage (From the date of receipt)	2 years -20°C liquid

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	H1 receptor
References	[1] https://pubmed.ncbi.nlm.nih.gov/17883909/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07709000	NOT_YET_RECRUITING	Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies	Merck Sharp & Dohme LLC	2026-09-11	PHASE2
NCT07570173	RECRUITING	B-cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	2026-05-18	PHASE2; PHASE3
NCT07542756	RECRUITING	Insomnia; Insomnia Disorder; Chronic Insomnia; Chronic Insomnia Disorder	University of Pennsylvania	2026-05-01	PHASE4
NCT04270409	ACTIVE_NOT_RECRUITING	Plasma Cell Myeloma	Sanofi	2020-06-16	PHASE3
NCT05896228	RECRUITING	Refractory Multiple Myeloma; Relapsed Multiple Myeloma	Benjamin T Diamond, MD	2024-02-20	PHASE2
NCT05977998	RECRUITING	Gastric Adenocarcinoma; Carcinomatosis	M.D. Anderson Cancer Center	2023-09-08	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):